跳至主要内容
临床试验/NCT00094146
NCT00094146已完成2 期

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

Novartis5 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2002年1月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Novartis
入组人数
160
试验地点
5
主要终点
The percent change at baseline compared to 6 months in body weight

研究概览

简要总结

This study is in patients with at least moderate obesity (Body Mass Index [BMI] > 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin.

The main purpose of the study is to find the lowest dose of Sandostatin LAR® Depot that safely helps overweight people lose weight. The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • You may qualify for this study if you:
  • are between the ages of 18-70 (male or female)
  • are at least moderately obese (BMI > 30 kg/m2 or approximately 30 or more pounds overweight)
  • and pass an oral glucose tolerance test (a 3 hour test to determine if your body produces too much insulin)

排除标准

  • You are not qualified for this study if you:
  • have diabetes
  • have been able to lose weight with diet and exercise alone
  • have previously received Sandostatin LAR® Depot

结局指标

主要结局

The percent change at baseline compared to 6 months in body weight

次要结局

  • Compare changes from baseline and at 6 months in body mass index (BMI), percentage of total body fat percentage of abdominal fat, leptin, and waist-to-hip ratio

研究者

发起方
Novartis
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验